A61K 39/0017
Combination vaccines based on whole cell diphtheria-tetanus-pertussis
Official title: {Combination vaccines based on whole cell diphtheria-tetanus-pertussis}
A61K39/0017 (Combination vaccines based on whole cell diphtheria-tetanus-pertussis) appears on 23 US grants and 26 published applications in this corpus.
Search patents in A61K- Granted patents
- 23
- Published applications
- 26
- Assignees
- 8
- Inventors
- 33
- Latest grant
- 8 Feb 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 1 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 2 |
| 2009 | 0 | 6 |
| 2010 | 0 | 2 |
| 2011 | 0 | 2 |
| 2012 | 2 | 1 |
| 2013 | 2 | 2 |
| 2014 | 3 | 1 |
| 2015 | 1 | 1 |
| 2016 | 2 | 1 |
| 2017 | 1 | 1 |
| 2018 | 2 | 2 |
| 2019 | 3 | 1 |
| 2020 | 1 | 1 |
| 2021 | 0 | 0 |
| 2022 | 1 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Immunogenic composition8 Feb 2022US 11,241,495 B2Glaxosmithkline Biologicals SA
- Injectable vaccines against multiple meningococcal serogroups2 Jun 2020US 10,668,142 B2Glaxosmithkline Biologicals SA
- Injectable vaccines against multiple meningococcal serogroups30 Apr 2019US 10,272,147 B2Glaxosmithkline Biologicals SA
- Immunogenic composition2 Apr 2019US 10,245,317 B2Glaxosmithkline Biologicals SA
- Immunogenic composition1 Jan 2019US 10,166,287 B2Glaxosmithkline Biologicals SA
- Immunogenic composition2 Jan 2020US 2020/0000911 A1Glaxosmithkline Biologicals SA
- Immunogenic composition3 Oct 2019US 2019/0298822 A1Glaxosmithkline Biologicals SA
- Injectable vaccines against multiple meningococcal serogroups30 Aug 2018US 2018/0243395 A1Glaxosmithkline Biologicals SA
- Immunogenic composition8 Mar 2018US 2018/0064806 A1Glaxosmithkline Biologicals SA
- Immunogenic composition9 Mar 2017US 2017/0065714 A1Glaxosmithkline Biologicals SA
Most cited
By later US patents
- Vaccine34US 6,013,264 ASmithKline Beecham Biologicals s.a. · 2000
- Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae24US 6,420,139 B12002
- Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae22US 5,723,283 AClassen Immunotherapies, Inc. · 1998
- Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae19US 5,728,385 AClassen Immunotherapies, Inc. · 1998
- Process for manufacturing vaccines17US 8,329,184 B2Glaxosmithkline Biologicals SA · 2012